| KVUE |
Report |
Adjusted EPS (Q2 FY26) |
BEAT |
pred ~$0.34 vs. cons $0.32 |
MEDIUM |
| KVUE |
Report |
Net Sales/Revenue (Q2 FY26) |
IN-LINE |
pred ~$4.03B vs. cons $4.00B |
MEDIUM |
| KVUE |
Report |
Skin Health & Beauty organic sales growth (Q2 FY26) |
MISS |
pred ~4.0% vs. cons 5.0% |
LOW |
| KVUE |
Guide |
FY2026 formal guidance (suspended due to merger) |
UNKNOWN |
guide ~withheld (implied $16.0B) vs. cons $16.0B (FY2026) |
LOW |
| KVUE |
Guide |
2026 Restructuring Initiative pre-tax charges |
UNCHANGED |
guide ~$250M vs. cons $250M (FY2026) |
HIGH |
| KVUE |
Guide |
Deal timing (H2 2026 close, pending EU clearance) |
UNCHANGED |
guide ~H2 2026 (0 new milestones) vs. cons H2 2026 (FY2026 close date) |
MEDIUM |
| KVUE |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.3% |
— |
LOW |
| KVUE |
Return |
5-day cumulative residual |
-0.6% (FADE) |
With no call and no restored guidance, any initial idiosyncratic pop from the EPS beat is likely to fade as (1) Skin Health & Beauty deceleration and continued Self Care softness raise implicit out-quarter estimate cuts even absent formal guidance, (2) the stock remains arbitrage-anchored to the fixed KMB exchange ratio (~$19.94 implied value) rather than standalone fundamentals, capping upside, and (3) the revived Tylenol autism litigation and pending EU merger clearance remain overhangs that dominate multi-day price action over fundamentals, pulling the initial reaction back toward the deal-implied spread within the week. |
LOW |